Corbus Outlines Phase 1 Results From ADC Trial for Bladder, Cervical Cancers
FDA Oncology Chief Says International Clinical Trials Should Be Priority
'Stick With What's Working' as Markets Head Into June Trade: Fundstrat's Tom Lee
Summit Lead Asset Approved in China for Lung Cancer
J&J Says Rybrevant Combo Bests AstraZeneca's Tagrisso in Type of Lung Cancer
Immunocore Touts Updated Phase 1 Results for Melanoma Asset Brenetafusp
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 1.01% on an annualized basis producing an average annual return of 8.86%. Currently, Amgen has a market capitalization of $161
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Novartis Boasts Scemblix Beats Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Moderna Wins FDA Approval for RSV Vaccine
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company's stock closed 272.1% higher at $10.92 on Thursday.Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients
Summit Pares Gains as 'China-only' Trial Beats Merck's Keytruda
How To Earn $500 A Month From Pfizer Stock
Shares of Pfizer Inc. (NYSE:PFE) closed higher during Thursday's session, with the company's stock adding around 10% over the past month.Pfizer recently launched a multi-year cost reduction initiative
Dividend Roundup: Meta Platforms, Merck, Cigna, Halliburton, and More
Pfizer Gene Therapy for Haemophilia B Therapy Endorsed in EU
The Committee For Medicinal Products For Human Use Of The European Medicines Agency Adopted A Positive Opinion For Pfizer's Fidanacogene Elaparvovec, A One-time Gene Therapy For Severe Hemophilia B In Adult Patients
The Committee For Medicinal Products For Human Use Of The European Medicines Agency Adopted A Positive Opinion For Pfizer's Fidanacogene Elaparvovec, A One-time Gene Therapy For Severe Hemophilia B In
AbbVie Wins EU Backing for Skyrizi in Bowel Disorder
Wall Street issuer creates “Lucky 8” Chinese giant ETF to target the “Seven Heroes” of US stock technology
① According to the document, the initial members of “Lucky Eight” were Tencent Holdings, Alibaba, Meituan, BYD, and Xiaomi, Pinduoduo, JD, and Baidu; ② Although some China Internet ETFs have provided exposure, Mazza hopes investors can focus on a few key targets in this field.
FDA Extends Priority Review Deadline For Regeneron Pharmaceuticals And Sanof's Dupixent For The Treatment Of COPD Patients With Type 2 Inflammation To September 2024
The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) a